Is vancomycin MIC "creep" method dependent? Analysis of methicillin-resistant Staphylococcus aureus susceptibility trends in blood isolates from North East Scotland from 2006 to 2010

Journal of Clinical Microbiology

Volumn 50, Issue 2, 2012, Pages 318-325

  Edwards, Becky ^a   Milne, K ^a   Lawes, T ^a   Cook, I ^a   Robb, A ^b   Gould, I M ^a  

^a ABERDEEN ROYAL INFIRMARY   (United Kingdom)

^b STOBHILL HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

DAPTOMYCIN; KANAMYCIN; NOVOBIOCIN; SULFAMETHOXAZOLE; TOBRAMYCIN; VANCOMYCIN;

ANTIBIOTIC SENSITIVITY; ARTICLE; AUTOMATION; BACTERIUM ISOLATE; BLOOD CULTURE; BROTH DILUTION; CONCENTRATION (PARAMETERS); INTERMETHOD COMPARISON; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; MIC CREEP; NONHUMAN; PRIORITY JOURNAL; PROSPECTIVE STUDY; RETROSPECTIVE STUDY; TREND STUDY; UNITED KINGDOM;

ANTI-BACTERIAL AGENTS; BACTEREMIA; BLOOD; DAPTOMYCIN; HUMANS; METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS; MICROBIAL SENSITIVITY TESTS; PROSPECTIVE STUDIES; RETROSPECTIVE STUDIES; SCOTLAND; STAPHYLOCOCCAL INFECTIONS; TIME FACTORS; VANCOMYCIN; VANCOMYCIN RESISTANCE;

METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS;

EID: 84856188702     PISSN: 00951137     EISSN: 1098660X     Source Type: Journal    
DOI: 10.1128/JCM.05520-11     Document Type: Article

References (36)

1. Alós J-I, García-Cañas A, García-Hierro P, Rodríguez-Salvanés F. 2008. Vancomycin MICs did not creep in Staphylococcus aureus isolates from 2002 to 2006 in a setting with low vancomycin usage. J. Antimicrob. Chemother. 62:773-775.
2. Chesneau O, Morvan A, El Solh N. 2000. Retrospective screening for heterogeneous vancomycin resistance in diverse Staphylococcus aureus clones disseminated in French hospitals. J. Antimicrob. Chemother. 45:887-890. (Pubitemid 30348962)
3. Dan M, Richardson J, Miliotis MD, Koornhof HJ. 1989. Comparison of preservation media and freezing conditions for storage of specimens of faeces. J. Med. Microbiol. 28:151-154.
4. Edwards B, Milne K, Lawes T, Cook I, Gould IM. 2011. Vancomycin susceptibility trends in MRSA isolated from blood cultures in Aberdeen Royal Infirmary from 2006-2010. Is vancomycin "creep" method dependent?, abstr. P765. Abstr. 21st Eur. Cong. Clin. Microbiol. Infect. Dis., 7 to 10 May 2011, Milan, Italy.
5. Gomez J, et al. 2007. Predictors of mortality in patients with methicillin-resistant Staphylococcus aureus (MRSA) bacteraemia: the role of empiric antibiotic therapy. Eur. J. Clin. Microbiol. Infect. Dis. 26:239-245. (Pubitemid 46572024)
6. Gould IM. 2010. Is vancomycin redundant for serious staphylococcal infection? Int. J. Antimicrob. Agents 36(Suppl 2):S55-S57.
7. Gudiol F, et al. 2009. Documento de consenso sobre el tratamiento de la bacteriemia y la endocarditis causada por Staphylococcus aureus resistente a la meticilina. Enferm. Infecc. Microbiol. Clin. 27:105-115.
8. Hawser SP, Bouchillon SK, Hoban DJ, Dowzicky M, Babinchak T. 2011. Rising incidence of Staphylococcus aureus with reduced susceptibility to vancomycin and susceptibility to antibiotics: a global analysis 2004-2009. Int. J. Antimicrob. Agents 37:219 -224.
9. Holmes RL, Jorgensen JH. 2008. Inhibitory activities of 11 antimicrobial agents and bactericidal activities of vancomycin and daptomycin against invasive methicillin-resistant Staphylococcus aureus isolates obtained from 1999 through 2006. Antimicrob. Agents Chemother. 52:757-760. (Pubitemid 351170860)
10. Howden BP, Davies JK, Johnson PDR, Stinear TP, Grayson ML. 2010. Reduced vancomycin susceptibility in Staphylococcus aureus, including vancomycin-intermediate and heterogeneous vancomycin-intermediate strains: resistance mechanisms, laboratory detection, and clinical implications. Clin. Microbiol. Rev. 23:99 -139.
11. Hsu DI, et al. 2008. Comparison of method-specific vancomycin minimum inhibitory concentration values and their predictability for treatment outcome of methicillin-resistant Staphylococcus aureus (MRSA) infections. Int. J. Antimicrob. Agents 32:378 -385.
12. Hunt AC, et al. 2011. Methicillin-resistant Staphylococcus aureus in northeastern Scotland in 2003 to 2007: evolving strain distribution and resistance patterns. J. Clin. Microbiol. 49:1975-1978.
13. Jones RN. 2006. Microbiological features of vancomycin in the 21st century: minimum inhibitory concentration creep, bactericidal/static activity, and applied breakpoints to predict clinical outcomes or detect resistant strains. Clin. Infect. Dis. 42(Suppl 1):S13-S24. (Pubitemid 41832061)
14. Kehrmann J, et al. 2011. Vancomycin MIC creep in MRSA blood culture isolates from Germany: a regional problem? Eur. J. Clin. Microbiol. Infect. Dis. 30:677- 683.
15. Kullar R, Davis SL, Levine DP, Rybak MJ. 2011. Impact of vancomycin exposure on outcomes in patients with methicillin-resistant Staphylococcus aureus bacteraemia: support for consensus guidelines suggested targets. Clin. Infect. Dis. 52:975-981.
16. Liu C, et al. 2011. Clinical practice guidelines by the Infectious Diseases Society of America for the treatment of methicillin-resistant Staphylococcus aureus infections in adults and children. Clin. Infect. Dis. 52:285-292.
17. Lodise TP, et al. 2008. Relationship between vancomycin MIC and failure among patients with methicillin-resistant Staphylococcus aureus bacteremia treated with vancomycin. Antimicrob. Agents Chemother. 52:3315-3320.
18. Lubin AS, Snydman DR, Ruthazer R, Bide P, Golan Y. 2011. Predicting high vancomycin minimum inhibitory concentration in methicillin-resistant Staphylococcus aureus bloodstream infections. Clin. Infect. Dis. 52:997-1002.
19. Moise PA, North D, Steenberg JN, Sakoulas G. 2009. Susceptibility relationship between vancomycin and daptomycin in Staphylococcus aureus: facts and assumptions. Lancet Infect. Dis. 9:617- 624.
20. Moise PA, Sakoulas G, Forrest A, Schentag JJ. 2007. Vancomycin in vitro bactericidal activity and its relationship to efficacy in clearance of methicillin-resistant Staphylococcus aureus bacteremia. Antimicrob. Agents Chemother. 51:2582-2586. (Pubitemid 47047340)
21. Moore C, et al. 2010. USA600 (ST45) methicillin-resistant Staphylococcus aureus bloodstream infections in urban Detroit. J. Clin. Microbiol. 48:2307-2310.
22. Musta AC, et al. 2009. Vancomycin MIC plus heteroresistance and outcome of methicillin-resistant Staphylococcus aureus bacteremia: trends over 11 years. J. Clin. Microbiol. 47:1640 -1644.
23. Ohkusa T, Miwa H, Endo S, Okayasu I, Sato N. 2004. Helicobacter pylori is a fragile bacteria when stored at low and ultra-low temperatures. J. Gastroenterol. Hepatol. 19:200 -204.
24. Patel N, et al. 2011. Vancomycin: we can't get there from here. Clin. Infect. Dis. 52:969 -974.
25. Paul M, et al. 2010. Importance of appropriate empirical antibiotic therapy for methicillin-resistant Staphylococcus aureus bacteraemia. J. Antimicrob. Chemother. 65:2658 -2665.
26. Robert J, Bismuth R, Jarlier V. 2006. Decreased susceptibility to glycopeptides in methicillin-resistant Staphylococcus aureus: a 20 year study in a large French teaching hospital, 1983-2002. J. Antimicrob. Chemother. 57:506 -510.
27. Rojas L, et al. 2010. Impact of vancomycin MIC and vancomycin serum levels on the outcome of methicillin-resistant Staphylococcus aureus (MRSA) bloodstream infection (BSI), abstr K-337. Abstr. Intersci. Conf. Antimicrob. Agents Chemother., Boston, MA.
28. Rybak MJ, et al. 2008. Characterization of vancomycin-heteroresistant Staphylococcus aureus from the metropolitan area of Detroit, Michigan, over a 22-year period (1986 to 2007). J. Clin. Microbiol. 46:2950 -2954.
29. Sader HS, et al. 2009. Evaluation of vancomycin and daptomycin potency trends (MIC creep) against methicillin-resistant Staphylococcus aureus isolates collected in nine U.S. medical centers from 2002 to 2006. Antimicrob. Agents Chemother. 10:4127- 4132.
30. Sader HS, Rhomberg PR, Jones RN. 2009. Nine-hospital study comparing broth microdilution and Etest method results for vancomycin and daptomycin against methicillin-resistant Staphylococcus aureus. Antimicrob. Agents Chemother. 53:3162-3165.
31. Sakoulas G, et al. 2004. Relationship of MIC and bactericidal activity to efficacy of vancomycin for treatment of methicillin-resistant Staphylococcus aureus bacteremia. J. Clin. Microbiol. 42:2398 -2402.
32. Soriano A, et al. 2008. Influence of vancomycin minimum inhibitory concentration on the treatment of methicillin-resistant Staphylococcus aureus bacteremia. Clin. Infect. Dis. 46:193-200. (Pubitemid 351269157)
33. Steinkraus G, White R, Friedrich L. 2007. Vancomycin MIC creep in non-vancomycin-intermediate Staphylococcus aureus (VISA), vancomycin-susceptible clinical methicillin-resistant S. aureus (MRSA) blood isolates from 2001-05. J. Antimicrob. Chemother. 60:788 -794.
34. Tenover FC. 2010. The quest to identify heterogeneously resistant vancomycin-intermediate Staphylococcus aureus strains. Int. J. Antimicrob. Agents 36:303-306.
35. Wang G, Hindler JF, Ward KW, Bruckner DA. 2006. Increased vancomycin MICs for Staphylococcus aureus clinical isolates from a university hospital during a 5-year period. J. Clin. Microbiol. 44:3883-3886. (Pubitemid 44737223)
36. Yoon YK, Kim JY, Park DW, Sohn JW, Kim MJ. 2010. Predictors of persistent methicillin-resistant Staphylococcus aureus bacteremia in patients treated with vancomycin. J. Antimicrob. Chemother. 65:1015-1018.